DexCom, Inc. (NASDAQ:DXCM) Receives Average Rating of “Moderate Buy” from Analysts

Shares of DexCom, Inc. (NASDAQ:DXCM) have been given an average recommendation of “Moderate Buy” by the twenty analysts that are currently covering the stock, Marketbeat.com reports. Four analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have assigned a strong buy rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $99.00.

Several research analysts recently issued reports on DXCM shares. Citigroup upped their target price on DexCom from $101.00 to $104.00 and gave the company a “buy” rating in a research report on Tuesday, March 4th. Canaccord Genuity Group upped their price objective on shares of DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a report on Friday, February 14th. Morgan Stanley lifted their target price on shares of DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research note on Friday, February 14th. Wells Fargo & Company reaffirmed an “overweight” rating on shares of DexCom in a report on Saturday, March 8th. Finally, Cfra Research raised DexCom to a “hold” rating in a research report on Friday, March 21st.

Insider Activity

In related news, EVP Michael Jon Brown sold 13,000 shares of DexCom stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $914,940.00. Following the sale, the executive vice president now directly owns 105,602 shares in the company, valued at approximately $7,432,268.76. The trade was a 10.96 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Kevin R. Sayer sold 33,359 shares of the stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $2,899,230.69. Following the transaction, the chief executive officer now directly owns 319,037 shares of the company’s stock, valued at $27,727,505.67. The trade was a 9.47 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 105,009 shares of company stock worth $8,044,178 over the last three months. 0.32% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Chicago Capital LLC grew its holdings in shares of DexCom by 75.0% during the first quarter. Chicago Capital LLC now owns 885,532 shares of the medical device company’s stock worth $60,473,000 after buying an additional 379,586 shares in the last quarter. Inscription Capital LLC purchased a new position in DexCom in the 1st quarter worth approximately $137,000. Grimes & Company Inc. acquired a new position in shares of DexCom during the 1st quarter worth approximately $9,215,000. QRG Capital Management Inc. grew its position in shares of DexCom by 26.2% in the first quarter. QRG Capital Management Inc. now owns 22,749 shares of the medical device company’s stock valued at $1,554,000 after purchasing an additional 4,716 shares in the last quarter. Finally, Sagespring Wealth Partners LLC increased its holdings in shares of DexCom by 96.1% in the first quarter. Sagespring Wealth Partners LLC now owns 10,552 shares of the medical device company’s stock valued at $721,000 after purchasing an additional 5,172 shares during the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Stock Performance

Shares of DexCom stock opened at $68.59 on Friday. The company has a market capitalization of $26.90 billion, a PE ratio of 47.97, a P/E/G ratio of 2.30 and a beta of 1.50. The company has a 50-day simple moving average of $75.33 and a two-hundred day simple moving average of $76.59. DexCom has a one year low of $57.52 and a one year high of $139.24. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Research analysts expect that DexCom will post 2.03 EPS for the current fiscal year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.